TY - JOUR
T1 - The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International
T2 - Active Surveillance JAPAN study
AU - Tohi, Yoichiro
AU - Kato, Takuma
AU - Matsumoto, Ryuji
AU - Shinohara, Nobuo
AU - Shiga, Kenichiro
AU - Yokomizo, Akira
AU - Nakamura, Masaki
AU - Kume, Haruki
AU - Mitsuzuka, Koji
AU - Sasaki, Hiroshi
AU - Egawa, Shin
AU - Matsumura, Masafumi
AU - Hashine, Katsuyoshi
AU - Inokuchi, Junichi
AU - Eto, Masatoshi
AU - Baba, Haruki
AU - Ichikawa, Tomohiko
AU - Kinoshita, Hidefumi
AU - Matsuda, Tadashi
AU - Kakehi, Yoshiyuki
AU - Sugimoto, Mikio
N1 - Funding Information:
Dr Nobuo Shinohara received honoraria from Takeda Pharmaceutical Co. Ltd, Bayer Co. Ltd, Astellas Pharmaceutical Co. Ltd, Ono Pharmaceutical Co. Ltd, Pfizer Co Ltd, Novartis Pharmaceutical Co. Ltd, and AstraZeneca Co. Ltd, and received research funding from Ono Pharmaceutical Co. Ltd and Astellas Pharmaceutical Co. Ltd. Dr Masatoshi Eto received honoraria from Takeda Pharmaceutical Co. Ltd and Janssen Pharmaceutical Co. Ltd, and received research funding from Sanofi Co. Ltd, Bayer Co. Ltd, Astellas Pharmaceutical Co. Ltd and Takeda Pharmaceutical Co. Ltd. Dr Shin Egawa received scholarship donations from Takeda Pharmaceutical Co. Ltd, Kissei Pharmaceutical Co. Ltd, Ono Pharmaceutical Co. Ltd and Bayer Co. Ltd. Dr Akira Yokomizo received honoraria from Astellas Pharmaceutical Co. Ltd, Sanofi Co. Ltd and Bayer Co. Ltd. Dr Mikio Sugimoto received honoraria from Astellas Pharmaceutical Co. Ltd, Janssen Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd and AstraZeneca Co. Ltd, and received researching funding from Astellas Pharmaceutical Co. Ltd, Janssen Pharmaceutical Co. Ltd, AstraZeneca Co. Ltd, Bayer Co. Ltd, Ono Pharmaceutical Co. Ltd, Shin Nippon Biomedical Laboratories Ltd, Eisai Co. Ltd, and Merck Ltd, and received scholarship donations from Astellas Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd, Bayer Co. Ltd and Pfizer Co Ltd. Other authors declare that they have no conflict of interest.
Publisher Copyright:
© 2020, Japan Society of Clinical Oncology.
PY - 2020/12
Y1 - 2020/12
N2 - Background: Patients with favorable-risk prostate cancer on active surveillance (AS) are strictly followed for safer execution. Repeat protocol biopsy is essential for evaluating cancer aggressiveness. However, the acceptance rate of repeat biopsy is not high enough because of the burdens of biopsy. We assessed the impact of complications after the initial biopsy on repeat protocol biopsy at 1 year using data from the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study. Methods: We performed a retrospective analysis using a prospective cohort in the PRIAS-JAPAN study. Patients with favorable-risk prostate cancer (n = 856) who consented to participate in the PRIAS-JAPAN study from 2010 to 2018 were enrolled. Follow-up evaluations included regular prostate-specific antigen, digital rectal examination and biopsy. Rates of complications after biopsies and repeat protocol biopsy non-acceptance rate at 1 year were reported. Logistic regression analysis explored the association between the complications after the initial biopsy and repeat protocol biopsy non-acceptance. Results: Altogether, 759 patients (88.7%) actually proceeded to protocol at 1 year. Repeat protocol biopsy non-acceptance rate at 1 year was 14.9%. Regarding complications after the initial biopsy, hematuria (p = 0.028) and pain (p < 0.001) rates were significantly higher in the repeat biopsy non-acceptance group, but infection (p = 0.056) and hematospermia (p = 0.337) rates were not different. On multivariate logistic regression analysis, pain was a significant predictor for repeat protocol biopsy non-acceptance (odds ratio 4.68, 95% confidence interval 1.864–11.75; p = 0.001). Conclusions: Pain at the initial biopsy negatively impacts patients’ compliance with further protocol biopsies during AS.
AB - Background: Patients with favorable-risk prostate cancer on active surveillance (AS) are strictly followed for safer execution. Repeat protocol biopsy is essential for evaluating cancer aggressiveness. However, the acceptance rate of repeat biopsy is not high enough because of the burdens of biopsy. We assessed the impact of complications after the initial biopsy on repeat protocol biopsy at 1 year using data from the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study. Methods: We performed a retrospective analysis using a prospective cohort in the PRIAS-JAPAN study. Patients with favorable-risk prostate cancer (n = 856) who consented to participate in the PRIAS-JAPAN study from 2010 to 2018 were enrolled. Follow-up evaluations included regular prostate-specific antigen, digital rectal examination and biopsy. Rates of complications after biopsies and repeat protocol biopsy non-acceptance rate at 1 year were reported. Logistic regression analysis explored the association between the complications after the initial biopsy and repeat protocol biopsy non-acceptance. Results: Altogether, 759 patients (88.7%) actually proceeded to protocol at 1 year. Repeat protocol biopsy non-acceptance rate at 1 year was 14.9%. Regarding complications after the initial biopsy, hematuria (p = 0.028) and pain (p < 0.001) rates were significantly higher in the repeat biopsy non-acceptance group, but infection (p = 0.056) and hematospermia (p = 0.337) rates were not different. On multivariate logistic regression analysis, pain was a significant predictor for repeat protocol biopsy non-acceptance (odds ratio 4.68, 95% confidence interval 1.864–11.75; p = 0.001). Conclusions: Pain at the initial biopsy negatively impacts patients’ compliance with further protocol biopsies during AS.
UR - http://www.scopus.com/inward/record.url?scp=85089253394&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089253394&partnerID=8YFLogxK
U2 - 10.1007/s10147-020-01761-3
DO - 10.1007/s10147-020-01761-3
M3 - Article
C2 - 32770439
AN - SCOPUS:85089253394
VL - 25
SP - 2107
EP - 2114
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
SN - 1341-9625
IS - 12
ER -